In the Boardroom - Oncology

Filter

Current filters:

Oncology

Popular Filters

Novartis nabs Merck's Bruno Strigini as president of oncology business

Novartis nabs Merck's Bruno Strigini as president of oncology business

01-06-2014

Swiss pharma major Novartis has announced the appointment of Bruno Strigini as president of Novartis…

BoardroomManagementOncologyPharmaceutical

Angle appointments new Scientific Adviser

Angle appointments new Scientific Adviser

26-03-2014

Angle (AIM:AGL), the specialist medtech company, has appointed Clive Stanway as a Scientific Adviser…

AngleBiotechnologyBoardroomCancer Research TechnologyOncologyUK

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Jonathan Knowles named as executive chairman of the board of Immunocore and Adaptimmune

Jonathan Knowles named as executive chairman of the board of Immunocore and Adaptimmune

20-11-2013

UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the…

AdaptimmuneBoardroomEuropeImmunocoreOncologyPharmaceuticalUK

Interview: Clinigen’s CEO Peter George on the company’s record growth

Interview: Clinigen’s CEO Peter George on the company’s record growth

15-11-2013

If there is one pharma company bucking the trend of shaky financial results it is the Clinigen Group.

BoardroomClinigen GroupFoscavirInterviewsOncologyPharmaceuticalRare diseasesUK

Back to top